Sabeluzole | CAS#104383-17-7 | NMDA antagonist

MedKoo Cat#: 326887 | Name: Sabeluzole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sabeluzole, also known as R-58735, is a nootropic and neuroprotective drug which was originally developed for the treatment of Alzheimer's disease, and has subsequently been researched for other applications such as sleep apnoea. It acts primarily as an NMDA antagonist, but other mechanisms of action may also be important. .

Chemical Structure

Sabeluzole

CAS#104383-17-7

Theoretical Analysis

MedKoo Cat#: 326887

Name: Sabeluzole

CAS#: 104383-17-7

Chemical Formula: C22H26FN3O2S

Exact Mass: 415.1730

Molecular Weight: 415.53

Elemental Analysis: C, 63.59; H, 6.31; F, 4.57; N, 10.11; O, 7.70; S, 7.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

R-58735; R58735; R 58735; Sabeluzole

IUPAC/Chemical Name

1-(4-((benzo[d]thiazol-2-ylmethyl)amino)piperidin-1-yl)-3-(4-fluorophenoxy)propan-2-ol

InChi Key

HCILMQWHTFQXRD-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H26FN3O2S/c23-16-5-7-19(8-6-16)28-15-18(27)14-26-11-9-17(10-12-26)24-13-22-25-20-3-1-2-4-21(20)29-22/h1-8,17-18,24,27H,9-15H2

SMILES Code

OC(COC1=CC=C(F)C=C1)CN2CCC(NCC3=NC4=CC=CC=C4S3)CC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 415.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Verreck G, Chun I, Li Y, Kataria R, Zhang Q, Rosenblatt J, Decorte A, Heymans K, Adriaensen J, Bruining M, Van Remoortere M, Borghys H, Meert T, Peeters J, Brewster ME. Preparation and physicochemical characterization of biodegradable nerve guides containing the nerve growth agent sabeluzole. Biomaterials. 2005 Apr;26(11):1307-15. PubMed PMID: 15475061. 2: Pageaux GP, Micallef J, Nataf MB, Levron JC, Lacarelle B, Le Moing JP, Bouhours P, Blin O. Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers. Br J Clin Pharmacol. 2001 Feb;51(2):164-8. PubMed PMID: 11259989; PubMed Central PMCID: PMC2014438. 3: Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, Mendis T. Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clin Neuropharmacol. 1997 Aug;20(4):338-45. PubMed PMID: 9260731. 4: Uberti D, Rizzini C, Galli P, Pizzi M, Grilli M, Lesage A, Spano P, Memo M. Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. Synapse. 1997 Jun;26(2):95-103. PubMed PMID: 9131769. 5: Geerts H, Nuydens R, De Jong M, Cornelissen F, Nuyens R, Wouters L. Sabeluzole stabilizes the neuronal cytoskeleton. Neurobiol Aging. 1996 Jul-Aug;17(4):573-81. PubMed PMID: 8832632. 6: Domány G, Barta-Szalai G, Matúz J, Ezer E, Schön I. Analogues of sabeluzole with gastric acid secretion inhibitory effect. Pharmazie. 1996 Jun;51(6):427-8. PubMed PMID: 8767854. 7: Hedner J, Grunstein R, Eriksson B, Ejnell H. A double-blind, randomized trial of sabeluzole--a putative glutamate antagonist--in obstructive sleep apnea. Sleep. 1996 May;19(4):287-9. PubMed PMID: 8776785. 8: Aldenkamp AP, Overweg J, Smakman J, Beun AM, Diepman L, Edelbroek P, Gutter T, Mulder OG, vt Slot B, Vledder B. Effect of sabeluzole (R 58,735) on memory functions in patients with epilepsy. Neuropsychobiology. 1995;32(1):37-44. PubMed PMID: 7566521. 9: Zgur T, Vodusek DB, Krzan M, Vrtovec M. Efficiency of the antihypoxic substance sabeluzole in patients with clinically and neurophysiologically evident diabetic polyneuropathy. Acta Neurol Scand. 1993 Nov;88(5):381. PubMed PMID: 8296540. 10: Li JY, Dahlström AB. Sabeluzole administration does not enhance fast axonal transport in normal adult rat sciatic nerve. Pharmacol Toxicol. 1993 Jun;72(6):383-7. PubMed PMID: 7689730. 11: Hlinák Z, Krejcí I. [Sabeluzole and flunarizine in memory processes: animal studies]. Cesk Psychiatr. 1993 Apr;89(2):91-3. Czech. PubMed PMID: 8403029. 12: Vondrácková D. [EMG findings in patients with diabetic polyneuropathy treated with sabeluzole]. Cesk Psychiatr. 1993 Apr;89(2):87-90. Czech. PubMed PMID: 8403028. 13: Van der Valk JB, Vijverberg HP. Chronic sabeluzole treatment of cultured rat cerebellar granule cells reduces N-methyl-D-aspartate-induced inward current. Eur J Pharmacol. 1993 Feb 23;232(1):131-4. PubMed PMID: 8458392. 14: Krejcí I, Hlinák Z, Schuh J. [Flunarizine and sabeluzole improves behavior disorders caused by cold-induced cortical lesions in mice]. Cesk Psychiatr. 1993 Jan;89(1):39-41. Czech. PubMed PMID: 8508463. 15: Krejcová H, Vondrácková D, Egerová Y, Cerný R. [Treatment of polyneuropathy using sabeluzole]. Cesk Psychiatr. 1993 Jan;89(1):35-8. Czech. PubMed PMID: 8508462. 16: Pauwels PJ, Van Assouw HP, Peeters L, Moeremans M, Leysen JE. Chronic treatment with sabeluzole protects cultured rat brain neurons from the neurotoxic effects of excitatory amino acids. Synapse. 1992 Dec;12(4):271-80. PubMed PMID: 1361247. 17: Hendriksen PH, Oey PL, Wieneke GH, Banga JD, van Dam PS. Antihypoxic treatment at an early stage of diabetic neuropathy: an electrophysiological study with sabeluzole. Acta Neurol Scand. 1992 Nov;86(5):506-11. PubMed PMID: 1336292. 18: Geerts H, Nuydens R, Nuyens R, Cornelissen F, De Brabander M, Pauwels P, Janssen PA, Song YH, Mandelkow EM. Sabeluzole, a memory-enhancing molecule, increases fast axonal transport in neuronal cell cultures. Exp Neurol. 1992 Jul;117(1):36-43. PubMed PMID: 1377635. 19: Geerts H, Nuydens R, Nuyens R, Cornelissen F. Sabeluzole accelerates neurite outgrowth in different neuronal cell lines. Restor Neurol Neurosci. 1992 Jan 1;4(1):21-32. doi: 10.3233/RNN-1992-4103. PubMed PMID: 21551650. 20: De Deyn PP, Van de Velde V, Verslegers W, Saerens J, Pickut BA, Clincke B, Woestenborghs R, Van Peer A. Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients. Eur J Clin Pharmacol. 1992;43(6):661-2. PubMed PMID: 1493851.